COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research has published an update on Cardiol Therapeutics Inc., reaffirming its BUY recommendation and maintaining the price target of USD 3.60. The report highlights the progress in patient recruitment for CardiolRx's two lead indications, acute myocarditis (AM) and recurrent pericarditis (RP), with expectations of significant near-term catalysts for the stock. Analyst Christian Orquera remains optimistic about the company's investment potential. For the full analysis, visit the link provided. -
-
-
